Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system

被引:42
作者
Vanlandingham, Dana L.
Keil, Shawn D. [1 ]
Horne, Kate McElroy
Pyles, Richard
Goodrich, Raymond P.
Higgs, Stephen
机构
[1] CaridianBCT Biotechnol, Lakewood, CO 80215 USA
关键词
APHERESIS PLATELETS; RIBOFLAVIN; LIGHT; TRANSFUSION; EPIDEMIC; RISK;
D O I
10.1111/j.1537-2995.2012.03717.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that has been responsible for a number of large-scale epidemics as well as imported cases covering a wide geographical range. As a blood-borne virus capable of mounting a high-titer viremia in infected humans, CHIKV was included on a list of risk agents for transfusion and organ transplant by the AABB Transfusion-Transmitted Diseases Committee. Therefore, we evaluated the ability of the Mirasol pathogen reduction technology (PRT) system (CaridianBCT Biotechnologies) to inactivate live virus in contaminated plasma and platelet (PLT) samples. STUDY DESIGN AND METHODS: Plasma, PLTs, and phosphate-buffered saline controls were spiked with CHIKV and treated with riboflavin and varying doses of ultraviolet (UV) light using the Mirasol PRT system. Samples were tested before and after treatment for cytotoxicity, interference, and virus titer by titration and quantitative real-time reverse transcriptionpolymerase chain reaction. RESULTS: A significant reduction in CHIKV titer of greater than 99% was recorded after treatment of plasma or PLTs with the Mirasol PRT system, and the titer reduction was directly proportional to the UV dose delivered to the samples. No cytotoxicity of interference was observed in any sample at any treatment dose. CONCLUSION: These data indicate that the Mirasol PRT system efficiently inactivated live CHIKV in plasma and PLTs and could therefore potentially be used to prevent CHIKV transmission through the blood supply.
引用
收藏
页码:284 / 290
页数:7
相关论文
共 50 条
  • [31] The utility of pathogen inactivation technology: a real-life example of Leishmania infantum inactivation in platelets from a donor with an asymptomatic infection
    Jimenez-Marco, Teresa
    Riera, Cristina
    Fisa, Roser
    Girona-Llobera, Enrique
    Sedeno, Matilde
    Goodrich, Raymond P.
    Pujol, Alba
    Guillen, Carmen
    Muncunill, Josep
    BLOOD TRANSFUSION, 2012, 10 (04) : 536 - 541
  • [32] Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction
    Sow, Cisse
    Bouissou, Amelie
    Girard, Yvette A.
    Singh, Gurvani B.
    Bounaadja, Lotfi
    Payrat, Jean-Marc
    Haas, Delphine
    Isola, Herve
    Lanteri, Marion C.
    Bringmann, Peter
    Grellier, Philippe
    TRANSFUSION, 2022, 62 (05) : 1073 - 1083
  • [33] Challenge study of the pathogen reduction capacity of the THERAFLEX MB-Plasma technology
    Reichenberg, S.
    Gravemann, U.
    Sumian, C.
    Seltsam, A.
    VOX SANGUINIS, 2015, 109 (02) : 129 - 137
  • [34] Assessment of dengue virus inactivation in random donor platelets using amotosalen and ultraviolet A illumination
    Kumar, Ankit
    Tiwari, Aseem Kumar
    Kumar, Satendra
    Biswas, Ashutosh
    Singh, Gurpreet
    Chatterjee, Kabita
    Chakroborty, Sourit
    Sunil, Sujatha
    ASIAN JOURNAL OF TRANSFUSION SCIENCE, 2022, 16 (01) : 67 - 72
  • [35] Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction
    Seghatchian, Jerard
    Struff, Wilhelm G.
    Reichenberg, Stefan
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2011, 38 (01) : 55 - 64
  • [36] Mirasol Pathogen Reduction Technology® treatment does not affect acute lung injury in a two-event in vivo model caused by stored blood components
    Silliman, C. C.
    Khan, S. Y.
    Ball, J. Bradley
    Kelher, M. R.
    Marschner, S.
    VOX SANGUINIS, 2010, 98 (04) : 525 - 530
  • [37] THERAFLEX ultraviolet C (UVC)-based pathogen reduction technology for bacterial inactivation in blood components: advantages and limitations
    Schulze, Torsten J.
    Gravemann, Ute
    Seltsam, Axel
    ANNALS OF BLOOD, 2022, 7
  • [38] The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model
    Custer, Brian
    Agapova, Maria
    Martinez, Rebecca Havlir
    TRANSFUSION, 2010, 50 (11) : 2461 - 2473
  • [39] Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment
    Keil, Shawn D.
    Bengrine, Abderrahmane
    Bowen, Richard
    Marschner, Susanne
    Hovenga, Nick
    Rouse, Lindsay
    Gilmour, Denise
    Duverlie, Gilles
    Goodrich, Raymond P.
    TRANSFUSION, 2015, 55 (07) : 1736 - 1744
  • [40] Photochemical inactivation of pathogens in platelets and plasma: Five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety
    Cazenave, J. -P.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2011, 18 (02) : 53 - 61